Trials / Unknown
UnknownNCT03789006
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Efficiency of Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil When Used in Combination With Tacrolimus and Prednisolone in Living Donor Kidney Transplantation
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- University of Khartoum · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antithymocyte Immunoglobulin (Rabbit) | Induction agent for living donor kidney transplantation |
| DRUG | Interleukin 2 Receptor Antagonist | Induction agent for living donor kidney transplantation |
Timeline
- Start date
- 2018-03-21
- Primary completion
- 2022-03-21
- Completion
- 2024-03-21
- First posted
- 2018-12-28
- Last updated
- 2019-01-03
Locations
1 site across 1 country: Sudan
Source: ClinicalTrials.gov record NCT03789006. Inclusion in this directory is not an endorsement.